Trending Now - Pharmaceutical Companies Urge Supreme Court to Reinstate Mail Access for Abortion Pill
WHO:
NBC News - Danco Laboratories and GenBioPro are the pharmaceutical companies involved in the appeal regarding the abortion pill.
WHAT:
Law Dork - The U.S. Court of Appeals for the Fifth Circuit issued a ruling that would ban the mailing of the abortion drug mifepristone during litigation, acknowledging that the order would have nationwide effect.
Law Dork - The ruling in Louisiana v. U.S. Food and Drug Administration immediately upended the post-Roe landscape in the United States.
Law Dork - The Fifth Circuit's ruling was part of a trio of issues where the court sought to exert control and influence beyond the Fifth Circuit states of Louisiana, Mississippi, and Texas.
NBC News - Danco Laboratories and GenBioPro requested the Supreme Court to temporarily allow patients to continue accessing the abortion pill mifepristone through the mail.
NBC News - Danco Laboratories filed an emergency appeal to the Supreme Court to restore mail access for the abortion pill Mifepristone.
The Washington Post - GenBioPro also requested the Supreme Court to allow continued access to the abortion pill through the mail.
WHERE:
The Washington Post - The U.S. Court of Appeals for the 5th Circuit is located in New Orleans, where the ruling was issued.
WHEN:
Law Dork - The Fifth Circuit ruling was issued on May 1.
Law Dork - The order from U.S. District Judge Reed O’Connor requiring Rhode Island Hospital to comply with a subpoena is due by May 14.
The Washington Post - The emergency appeal was filed on a Saturday following a ruling issued on the previous Friday.
WHY:
NBC News - The appeal was prompted by a ruling from the 5th Circuit that made it harder for women to access the abortion pill.
HOW:
NBC News - The pharmaceutical companies are asking the Supreme Court to weigh in on the issue of mail access for the abortion pill.
(UPDATED May 4, 2026 13:20 UTC)
The U.S. Court of Appeals for the Fifth Circuit has issued a ruling that bans the mailing of the abortion drug mifepristone during ongoing litigation, a decision that will have a nationwide impact. This ruling in Louisiana v. U.S. Food and Drug Administration significantly alters the post-Roe landscape in the United States and reflects the court's intention to extend its influence beyond the states of Louisiana, Mississippi, and Texas. Additionally, U.S. District Judge Reed O’Connor has mandated that Rhode Island Hospital comply with a subpoena by May 14.
--
(UPDATED May 4, 2026 01:27 UTC)
Danco Laboratories and GenBioPro have asked the Supreme Court to temporarily permit patients to continue receiving the abortion pill mifepristone by mail. This request comes as part of ongoing legal discussions surrounding access to the medication. The outcome of this appeal could significantly impact how patients obtain this crucial healthcare option.
--
(UPDATED May 3, 2026 15:11 UTC)
Danco Laboratories and GenBioPro have filed an emergency appeal to the Supreme Court seeking to restore mail access for the abortion pill Mifepristone, following a ruling from the 5th Circuit that made it more difficult for women to obtain the medication. The appeal was submitted on a Saturday, just after the ruling was issued the previous Friday in New Orleans. Both companies are urging the Supreme Court to intervene on this critical issue of access to the abortion pill through the mail.